Background Investigation Methods
EPA Prioritizes TSCA Review of New Chemicals Used in Data Centers
Efforts are underway to support data center development with respect to new chemicals that may be used in such projects. EPA has provi...
Should Claims of a Link Between Tylenol/Acetaminophen Use and Autism Prompt Regulatory and Litigation Risks, Insurance Coverage May Offer Key Protection
As debate intensifies over acetaminophen and autism claims, manufacturers, distributors and health care providers should review coverag...
New York secures over $19 million in settlements from auto insurers over data breaches
On October 14, both the New York Office of the Attorney General (OAG) and NYDFS announced settlements totaling more than $19 million wi...
BIOSECURE Act included in Senate version of the 2026 NDAA
On October 9, the U.S. Senate adopted amendment 3841, adding Section 881, Prohibition on Contracting with Certain Biotechnology Provide...
NYC Mayor Adams establishes Office of Digital Assets and Blockchain Technology
On October 14, New York City Mayor Eric Adams signed an executive order creating the Office of Digital Assets and Blockchain Technology...
NYDFS outlines risks and trends with third-party service providers
On October 21, NYDFS issued an industry letter emphasizing several risks entities face when relying on third-party service providers. N...
“Untenable.” Federal California District Court Calls for Legislative Action on CIPA
On Friday, October 17, 2025, U.S. District Court Judge Vince Chhabria issued a biting Order granting defendant Eating Recovery Center, ...
Coalition of state attorneys general calls for SEC to create clear, narrow definitions for cryptoassets
On October 20, a coalition of 21 state attorneys general submitted a joint comment letter to the SEC in response to the agency’s reques...
The OpenAI NY Times Case is a Blueprint for AI Discovery: eDiscovery Trends
The OpenAI NY Times case is becoming a blueprint for the handling of discovery of AI-related content in litigation. Here’s why.
The pos...
Lessons for Biopharma From the Battle of Entresto®
After more than six years of high-stakes litigation in multiple courts and regulatory fights at the Food and Drug Administration (FDA),...